Letter to the editor: radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers.
J Immunother Cancer
; 9(7)2021 07.
Article
em En
| MEDLINE
| ID: mdl-34315822
ABSTRACT
A commentary on the original research article 'Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers'. Of note, the predictor selection process, the cross-validation method, along with the lack of final testing of the developed model with a separated data set may mask overfitting, overestimating performance metrics.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Anticorpos Monoclonais Humanizados
/
Neoplasias
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article